Altana denies delay of Daxas launch

Germany's Altana is denying rumors that it is planning to delay the US launch of its respiratory drug Daxas. Its stock has been hit by talk of a delay. The drug, which has been tapped as a potential blockbuster, is currently in a Phase III US trial. European regulators are considering Altana's marketing application.

- read this story from AFX for more